ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements with these filters
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
Biocon has initiated the remittance of the final dividend for FY 2025-26. This notification confirms the dispatch process for shareholders.
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
Biocon received marketing approval from Japan's MHLW for its Pegfilgrastim biosimilar. This approval enhances Biocon's biosimilar portfolio and market access in Japan.
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.
Biocon Q1 FY27 revenue grew 10% YoY to INR 3,433 Cr. Biopharmaceuticals grew 17% while Services declined 16%. Group EBITDA was INR 902 Cr (21% margin) and Net Profit jumped 245% to INR 145 Cr.
Biocon Limited announced the re-appointment of Director Eric Vivek Mazumdar, retirement of Director Nicholas Robert Haggar, and appointment of S.R. Batliboi & Associates as new statutory auditors.
Biocon Limited held its 48th Annual General Meeting on August 06, 2026. The meeting transacted key business including adoption of financial statements and declaration of final dividend.
Biocon reported Q1 FY27 revenue of ₹4,336 Cr (up 10% YoY) and Net Profit (before exceptional) of ₹145 Cr (up 245% YoY). Strategy focuses on North American biosimilar launches and generic margin expansion.
Biocon Ltd filed its Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its previous QIP.
Biocon reported Q1 FY27 consolidated total income of Rs 4,391 crore and a net profit of Rs 141 crore. The release highlights growth across key business segments.
Biocon Ltd reported revenue from operations of ₹4,336 Cr (+10.0% YoY) and net profit of ₹136.8 Cr (+53.4% YoY) for Q1 FY27.
Biocon Limited has commercially launched 'Yesafili', a biosimilar to Eylea, in the United States market. This product strengthens the company's ophthalmology portfolio.
Biocon received Health Canada approval for its Yesintek (ustekinumab) Autoinjector Pen. This new product format expands the company's immunology portfolio in Canada.
Biocon scheduled a board meeting for August 05, 2026, to approve the financial results for the quarter ended June 30, 2026. An earnings call follows.
Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale on July 14, 2026.
Biocon Limited announced that Independent Director Mr. Bobby Kanubhai Parikh has ceased to be a Director following the completion of his second tenure.
Biocon Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings across promoter, institutional, and public categories.
Biocon received EMA approval for a new insulin fill finish line in Malaysia. Supplies to the European market are expected to commence from Q2FY27.
Biocon Limited convened its 48th AGM for August 6, 2026. Key agenda items include a 10% dividend declaration and adoption of a new long-term incentive plan.
Biocon Limited has released its Integrated Annual Report for FY 2025-26. The company's 48th Annual General Meeting is scheduled for August 06, 2026.
Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale.
Biocon announced the publication of Phase III clinical data supporting the effectiveness of its biosimilar Yesafili™. The data reinforces clinical equivalence ahead of its US launch.